References
- Singh AK, Carroll K, Perkovic V, et al. Daprodustat for the treatment of anaemia in patients undergoing dialysis. N Engl J Med. 2021. doi:https://doi.org/10.1056/NEJMoa2223379.
- Singh AK, Carroll K, McMurray JJV, et al. Daprodustat for the treatment of anaemia in patients not undergoing dialysis. N Engl J Med. 2021. doi:https://doi.org/10.1056/NEJMoa2223380. •Important phase 3 trial of daprodustat in subjects with anaemia in CKD not undergoing dialysis.
- NIH National institute of diabetes and digestive and kidney disease. Anaemia in chronic kidney disease. [cited 2021 Dec 21]. Available from: https://www.niddk.nih.gov/health-information/kidney-disease/anemia
- Babitt JL, Herbert YL. Mechanisms of anaemic in CKD. J Am Soc Nephrol. 2012;23:1631–1634.
- Lenihan CR, Winkelmayer WC. The dawning of a new day in CKD anemia care? J Am Soc Nephrol. 2016;968–970. DOI:https://doi.org/10.1681/ASN.2015091009
- Meadowcroft AM, Cizman B, Holdstock L, et al. Daprodustat for anaemia: a 24-week, open-labels randomized controlled trial in participants on hemodialysis. Clin Kidney J. 2019;12:139–148.
- Holdstock L, Cizman B, Meadowcroft AM, et al. Daprodustat for anaemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clin Kidney J. 2019;12:129–138.
- Tang M, Zhu C, Yan T, et al. Safe and effective treatment for anemic patients with chronic kidney disease: an updated systematic review and meta-analysis on roxadustat. Front Pharmacol. 2021;12:658079.
- Barratt J, Sulowicz W, Schömig M. Efficacy and cardiovascular safety of roxadustat in dialysis-dependent chronic kidney disease: pooled analysis of four phase 3 studies. Adv Ther. 2021;38:5345–5360.
- Chertow GM, Pergola PE, Farag YMK, et al., Vadadustat in patients with anemia and non-dialysis dependent CKD. N Eng J Med. 2021;384(17):1589–1600.
- Eckardt K-U, Agrawak R, Aswad A, et al. Safety and efficacy of vadadustat for anemia in patients undergoing dialysis. N Eng J Med. 2021;384:1601–1612.
- Singh AK, Blackorby A, Cizman B, et al. Study design and baseline characteristics of patients on dialysis in the ASCENT-D trial. Nephrol Dial Transplant. 2021. DOI:https://doi.org/10.1092/ndt/gfab065.
- ClinicalTrials.gov. Post-marketing surveillance of EVRENZO Tablets (Roxadustat) in patients with renal anemia. [cited 2022 Mar 21]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04408820?term=roxadustat&draw=2&rank=3
- Schneider J, Davies S, Howarth A. M0551 A cost-offset analysis of the roxadustat dialysis-dependent global phase 3 program: a Canadian healthcare perspective. Nephrol Dial Transplant. 2021;36(Suppl 1). DOI:https://doi.org/10.1093/ndt/gfab085.0014
- Hu Z, Tao H, Shi A, et al. The efficacy and economic evaluation of roxadustat treatment for anaemia in patients with kidney disease not receiving dialysis. Expert Rev Pharmacoecon Outcomes Res. 2020;20:411–418.
- Liu AA. FibroGen hope to keep their roxadustat dream alive with new FDA meeting. Fierce Pharma https://www.fiercepharma.com/marketing/astrazeneca-fibrogen-keep-roxadustat-s-anemia-dream-alive-new-fda-meeting [cited 2022 Jan 4].